{"id":13389,"date":"2023-04-17T16:25:51","date_gmt":"2023-04-17T16:25:51","guid":{"rendered":"http:\/\/lynettelockhart.com\/client\/ravgen-settles-patent-fight\/"},"modified":"2023-04-17T16:29:10","modified_gmt":"2023-04-17T16:29:10","slug":"ravgen-settles-patent-fight","status":"publish","type":"post","link":"http:\/\/lynettelockhart.com\/client\/ravgen-settles-patent-fight\/","title":{"rendered":"Ravgen settles patent fight with Illumina over genetic testing"},"content":{"rendered":"\n<p>(Reuters) &#8211;     Gene-sequencing giant Illumina Inc has settled a patent lawsuit brought by Maryland biotech company Ravgen Inc, which accused Illumina&#8217;s genetic tests of infringing its patents.<\/p>\n<p>The companies told a Delaware federal court Friday that they settled the case. Ravgen attorney John Desmarais on Monday called it &#8220;a mutually satisfactory settlement between the two parties&#8221; but did not disclose terms of the deal, which are confidential.<\/p>\n<p>San Diego-based Illumina declined to comment on Monday.<\/p>\n<p>Ravgen has filed a series of lawsuits against companies including Illumina, Natera and Roche&#8217;s Ariosa Diagnostics over DNA-testing technology. It won a $272 million jury verdict against Labcorp in Texas last September and settled a lawsuit against Quest Diagnostics shortly before a trial was set to begin in October.<\/p>\n<p>Ravgen alleged in its 2020 complaint that Illumina&#8217;s Verifi and VeriSeq tests for fetal chromosome abnormalities and TruSight test for cancer markers infringe its patents. Ravgen&#8217;s patents relate to less invasive diagnostic tests that analyze free-floating DNA from a patient&#8217;s bloodstream, technology the Columbia, Maryland-based company said it pioneered.<\/p>\n<p>Illumina denied the allegations and argued the patents were invalid.<\/p>\n<p>A jury trial was scheduled to begin next October.<\/p>\n<p>The case is Ravgen Inc v. Illumina Inc, U.S. District Court for the District of Delaware, No. 1:20-cv-01644.<\/p>\n<p \/>\n<p> (Reporting by Blake Brittain in Washington)<\/p>\n<p><a href=\"http:\/\/lynettelockhart.com\/client\/ravgen-settles-patent-fight\/file-photo-illuminas-global-headquarters-is-pictured-in-san-diego\/\"><img decoding=\"async\" src=\"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ3G0L4-VIEWIMAGE.jpg\" alt=\"tagreuters.com2023binary_LYNXMPEJ3G0L4-VIEWIMAGE\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>(Reuters) &#8211; Gene-sequencing giant Illumina Inc has settled a patent lawsuit brought by Maryland biotech company Ravgen Inc, which accused Illumina&#8217;s genetic tests of infringing its patents. The companies told a Delaware federal court Friday that they settled the case. Ravgen attorney John Desmarais on Monday called it &#8220;a mutually satisfactory settlement between the two [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":13390,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"spay_email":"","footnotes":""},"categories":[1213],"tags":[],"class_list":["post-13389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-u-s-business"],"jetpack_featured_media_url":"http:\/\/lynettelockhart.com\/client\/wp-content\/uploads\/Reuters_Direct_Media\/USOnlineReportBusinessNews\/tagreuters.com2023binary_LYNXMPEJ3G0L4-VIEWIMAGE.jpg","_links":{"self":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/13389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/comments?post=13389"}],"version-history":[{"count":1,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/13389\/revisions"}],"predecessor-version":[{"id":13391,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/posts\/13389\/revisions\/13391"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media\/13390"}],"wp:attachment":[{"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/media?parent=13389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/categories?post=13389"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/lynettelockhart.com\/client\/wp-json\/wp\/v2\/tags?post=13389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}